Chikeka Kelechi, Gbadamosi Kikelola, Tran Haijing, Chughtai Imran, Muhammad Sheheryar, Senay Meriam, Lam Beatrix, Ngouajio-Teguiafa Lynne, Nonyel Nkem, DeLaine Letitia, McSwain Chelsea, Price DeAngelo, Michaels Karen
Holy Cross Hospital, Silver Spring, MD, USA.
Hosp Pharm. 2023 Jun;58(3):277-281. doi: 10.1177/00185787221139429. Epub 2023 Jan 16.
The objective of this study is to determine the impact of a 48-hour time-out on the utilization of targeted empiric intravenous (IV) antibiotics through a systematic approach. This is a single-center, prospective, interventional study approved by the Institutional Review Board. Study groups were stratified into a control and intervention arm. Inclusion criteria consisted of patients 18 years of age or greater, on targeted broad-spectrum IV antibiotics for more than 24 hours: daptomycin, ertapenem, meropenem, piperacillin-tazobactam, vancomycin. Exclusion criteria included febrile neutropenic, pregnant, critically ill, and surgical prophylactic patients. Targeted interventions made by pharmacists included: IV to oral conversions, dose optimizations/adjustments, and de-escalations. Primary endpoints were days of therapy per 1000 patient days (DOT/1000), days of therapy at risk per 1000 patient days (DOT/1000 DAR), and de-escalation rates. Table 1 depicts a total 88.69% mean reduction of DOT/1000 of the intervention arm for vancomycin, piperacillin/tazobactam, and meropenem (-value <.0001) when compared to the control arm. Table 2 depicts a total 88.86% mean reduction of DOT/1000 DAR of the intervention arm for vancomycin, piperacillin/tazobactam, and meropenem (-value <.0001) when compared to control. Table 3 shows a 77.11% increase in total de-escalation rates (-value = .0107) in the intervention group when compared to control group (63.52%). This study displays the essential role that pharmacists play in antibiotic stewardship. This study further reveals that the stewarding tool utilized contributed to significant reductions in the usage of targeted empiric intravenous antibiotics.
本研究的目的是通过系统的方法确定48小时暂停对靶向经验性静脉注射(IV)抗生素使用的影响。这是一项经机构审查委员会批准的单中心、前瞻性、干预性研究。研究组分为对照组和干预组。纳入标准包括年龄在18岁及以上、接受靶向广谱静脉注射抗生素治疗超过24小时的患者:达托霉素、厄他培南、美罗培南、哌拉西林-他唑巴坦、万古霉素。排除标准包括发热性中性粒细胞减少症患者、孕妇、重症患者和手术预防性用药患者。药剂师进行的靶向干预包括:从静脉注射改为口服、剂量优化/调整以及降阶梯治疗。主要终点是每1000患者日的治疗天数(DOT/1000)、每1000患者日的危险治疗天数(DOT/1000 DAR)和降阶梯率。表1显示,与对照组相比,干预组万古霉素、哌拉西林/他唑巴坦和美罗培南的DOT/1000平均降低了88.69%(P值<.0001)。表2显示,与对照组相比,干预组万古霉素、哌拉西林/他唑巴坦和美罗培南的DOT/1000 DAR平均降低了88.86%(P值<.0001)。表3显示,与对照组(63.52%)相比,干预组的总降阶梯率增加了77.11%(P值 = .0107)。本研究显示了药剂师在抗生素管理中所起的重要作用。本研究进一步表明,所使用的管理工具有助于显著减少靶向经验性静脉注射抗生素的使用。